Sacubitril‐Valsartan in a routine community population: attention to volume status critical to achie...
Sacubitril‐Valsartan in a routine community population: attention to volume status critical to achieving target dose
About this item
Full title
Author / Creator
Publisher
England: John Wiley & Sons, Inc
Journal title
Language
English
Formats
Publication information
Publisher
England: John Wiley & Sons, Inc
Subjects
More information
Scope and Contents
Contents
Aims
In the PARADIGM‐heart failure trial, sacubitril‐valsartan demonstrated a reduction in heart failure admissions and reduced all‐cause mortality in patients with heart failure with reduced ejection fraction. Although real world data have shown similar benefits regarding efficacy and safety, there has been difficulty in achieving the target do...
Alternative Titles
Full title
Sacubitril‐Valsartan in a routine community population: attention to volume status critical to achieving target dose
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_7380faf93da2419aaa0f16bf7514d566
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_7380faf93da2419aaa0f16bf7514d566
Other Identifiers
ISSN
2055-5822
E-ISSN
2055-5822
DOI
10.1002/ehf2.12547
